China rejects the patent application of salvdi

Recently, a propaganda organization in the United States said that China rejected the patent application for Geely de hepatitis C, which may lead other countries to consider rejecting the patent for the controversial drug Sovaldi, a hepatitis C drug, will cost up to $84000 for a 12 week course in the US at $1000 per tablet Gilead also caught fire, with patent disputes in the US, India and Europe The New York based drug acquisition and knowledge Initiative (i-mak) said China rejected patent applications for precursor drugs, which are themselves inactive and converted into chemically active drugs in vivo However, Gilead still holds the patent of sovaldi (sofosbuvir) base compound in China, and the rejection of the patent does not mean that China, the world's second largest pharmaceutical market, has opened the door to sovaldi's generic drugs There was no response from Chinese officials or Gilead's US office Officials from China's State Intellectual Property Office have yet to confirm the decision, but its official website shows that Gilead's patent application for a "nucleoside aminophosphate" (a precursor drug) was recently rejected After the Indian Patent Office rejected Geely's sovaldi patent application in January, Geely was under pressure to sell the drug at a lower price in 91 developing countries However, five developing countries, China, Argentina, Brazil, Russia and Ukraine, are not in the agreement, which brings legal challenges to Gilead's patents and patent applications In addition, European charities are challenging Geely's patents for the price of hepatitis C drugs The World Health Organization says as many as 150 million people around the world are infected with chronic hepatitis C, most of them in low - and middle-income countries Recently, the who has added sovaldi to the list of essential drugs and asked it to be sold at a lower price, especially in middle-income countries Source: China projects patent l entered to Gilead patents C drug